# US 7,612,170 B2 · Co-stimulatory polypeptides > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 7,612,170 B2 - Document ID: US7612170B2 - Status: Granted - Kind: B2 - Application number: 11/332,037 - Filed: 2006-01-13 - Published: 2006-11-30 - Granted: 2009-11-03 - Earliest claimed: 2000-06-23 - Assignees: Maxygen, Inc. - Inventors: Juha Punnonen; Alexandra L. L. Lazetic; Steven R. Leong; Jean Chia-Chun Chang - Web page: https://patentgrep.com/patent/US7612170B2 ## CPC - C07K 14/70503: {Immunoglobulin superfamily} - A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) ## Abstract The invention provides polynucleotides and polypeptides encoded therefrom having advantageous properties, including an ability of the polypeptides to preferentially bind a CD28 or CTLA-4 receptor at a level greater or less than the ability of human B7-1 to bind CD28 or CTLA-4, or to induce or inhibit altered level of T cell proliferation response greater compared to that generated by human B7-1. The polypeptides and polynucleotides of the invention are useful in therapeutic and prophylactic treatment methods, gene therapy applications, and vaccines. ## Claims ### Claim 1 An isolated or recombinant polypeptide comprising a polypeptide sequence having at least 99% amino acid sequence identity to the polypeptide sequence of an extracellular domain of SEQ ID NO:86, wherein the polypeptide binds CTLA-4 or an extracellular domain of CTLA-4. ### Claim 2 (depends on 1) The polypeptide of claim 1, wherein the polypeptide has a CTLA-4/CD28 binding affinity ratio equal to or greater than the CTLA-4/CD28 binding affinity ratio of the extracellular domain of human B7-1. ### Claim 3 (depends on 1) The polypeptide of claim 1, wherein the polypeptide has an ability to inhibit T cell proliferation. ### Claim 4 (depends on 1) The polypeptide of claim 1 wherein the extracellular domain of SEQ ID NO:86 comprises amino acid residues 35-242 of SEQ ID NO:86. ### Claim 5 (depends on 1) The polypeptide of claim 1, wherein the polypeptide comprises amino acid residues 35-242 of SEQ ID NO:86. ### Claim 6 An isolated or recombinant polypeptide comprising (i) a first polypeptide comprising a polypeptide sequence having at least 99% amino acid sequence identity to the polypeptide sequence of an extracellular domain of SEQ ID NO:86, wherein the first polypeptide has a CTLA-4/CD28 binding affinity ratio equal to or greater than the CTLA-4/CD28 binding affinity ratio of the extracellular domain of human B7-1, and (ii) a second polypeptide comprising at least a portion of an immunoglobulin (Ig) polypeptide. ### Claim 7 (depends on 6) The polypeptide of claim 6, wherein the second polypeptide is an Ig polypeptide comprising a hinge, a CH2 domain and a CH3 domain. ### Claim 8 (depends on 7) The polypeptide of claim 7, wherein the second polypeptide is an IgG polypeptide comprising a hinge, a CH2 domain, and a CH3 domain. ### Claim 9 (depends on 6) The polypeptide of claim 6, wherein the polypeptide comprises amino acid residues 35-242 of SEQ ID NO:86. ### Claim 10 (depends on 6) A multimer comprising at least two polypeptides of claim 6. ### Claim 11 (depends on 1) The polypeptide of claim 1, wherein the polypeptide has an enhanced binding affinity for CTLA-4 as compared to the binding affinity of human B7-1 for CTLA-4. ### Claim 12 (depends on 1) A composition comprising the polypeptide of claim 1 and a pharmaceutically acceptable excipient or carrier. ### Claim 13 (depends on 1) An isolated or recombinant protein comprising the polypeptide of claim 1 and a signal peptide. ### Claim 14 (depends on 1) The polypeptide of claim 1, wherein the polypeptide is expressed on a cell or bound to a cell membrane. ### Claim 15 An isolated or recombinant polypeptide comprising a polypeptide sequence having at least 98% amino acid sequence identity to the polypeptide sequence of a mature domain of SEQ ID NO:86, wherein the polypeptide has a CTLA-4/CD28 binding affinity ratio equal to or greater than the CTLA-4/CD28 binding affinity ratio of the mature domain of human B7-1 or an ability to inhibit T cell proliferation. ### Claim 16 (depends on 15) The polypeptide of claim 15, wherein the mature domain of SEQ ID NO:86 comprises amino acid residues 35-288 of SEQ ID NO:86. ### Claim 17 (depends on 15) The polypeptide of claim 15, wherein the polypeptide comprises amino acid residues 35-288 of SEQ ID NO:86. ### Claim 18 (depends on 15) The polypeptide of claim 15, wherein the polypeptide is expressed on a cell or bound to a cell membrane. ### Claim 19 An isolated or recombinant polypeptide comprising a polypeptide sequence having at least 98% amino acid sequence identity to the full-length polypeptide sequence of SEQ ID NO:86, wherein the polypeptide binds CTLA-4 or inhibits T cell proliferation. ### Claim 20 (depends on 19) The polypeptide of claim 19, wherein the polypeptide has a CTLA-4/CD28 binding affinity ratio equal to or greater than the CTLA-4/CD28 binding affinity ratio of human B7-1. ### Claim 21 (depends on 19) The polypeptide of claim 19, wherein the polypeptide comprises the full-length sequence of SEQ ID NO:86.